After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.
Anavex announced new data from their phase 2b/3 Alzheimer's trial, which was presented at the CTAD 2024 conference. Read why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback